###### Clinical Perspective

What Is New?
============

-   This is the first study to genetically delete the necessary cardiogenic transcription factors *Gata4/6* from c-Kit^+^ cardiac progenitor cells, which remarkably resulted in greater apparent cardiomyocyte derivation from these c-Kit^+^ cells.

-   Deletion of *Gata4* from c-Kit--derived endothelial progenitors alters the integrity of the endothelial cell network in the heart, resulting in more c-Kit^+^--derived leukocytes entering the heart and fusing with cardiomyocytes.

-   We demonstrate a new role for Gata4 in endothelial differentiation, specifically showing for the first time that Gata4 is essential for vascular development via the c-Kit lineage.

-   This study shows that leukocyte-to-cardiomyocyte fusion is the primary basis for past lineage-tracing results incorrectly suggesting that c-Kit^+^ cardiac progenitor cells generated de novo cardiomyocytes in the heart.

What Are the Clinical Implications?
===================================

-   Our data demonstrate that c-Kit^+^ cardiac progenitor cells are much less likely to differentiate de novo into cardiomyocytes than previously reported, suggesting that such cells are not therapeutically meaningful as a source of new cardiomyocytes.

-   Our study highlights a capillary-driven mechanism of increased fusion of bone marrow--derived cells (leukocytes) with existing cardiomyocytes, which could have significant clinical implications in its own right.

-   *Kit* lineage and global endothelial cell deletion of *Gata4* reveal apparent organ-specific regulation of microvascular differentiation, highlighting Gata4 as a potential target for angiogenic control in the human heart.

Large-scale cardiomyocyte loss from a cardiac ischemic event initially elicits a dramatic inflammatory response, followed by fibroblast activation with scar formation and fibrosis, and then ventricular remodeling and eventually heart failure.^[@R1]^ To combat this profile of progressive cardiac deterioration after ischemic injury, cell-specific approaches have emerged with emphasis on altering the hematopoietic response,^[@R2]^ ameliorating fibrotic remodeling,^[@R3]--[@R6]^ increasing collateral circulation,^[@R7],[@R8]^ and preserving or replacing cardiomyocytes.^[@R9],[@R10]^ Earlier reports that endogenous cardiac stem cells exist and might be efficacious in mediating cardiac regeneration generated a great deal of excitement in the field.^[@R11],[@R12]^ c-Kit^+^ cardiac progenitor cells (CPCs), named for the presence of c-Kit tyrosine kinase receptor that marks hematopoietic stem cells,^[@R13]^ have been the focus of numerous cardiac regenerative studies.^[@R14]--[@R16]^ Select clinical trials evaluating the administration of bone marrow cells after myocardial infarction have shown minimal efficacy.^[@R17]--[@R19]^ However, expanded cardiac c-Kit^+^ cells were reported to potentially impart greater functional benefit with scar reduction when administered to patients post--myocardial infarction injury.^[@R20],[@R21]^

Although injection of exogenously expanded CPCs may indeed positively impact the myocardial infarction--injured heart, several recent studies have definitively shown that the heart lacks an endogenous c-Kit^+^ CPC capable of producing new cardiomyocytes in vivo.^[@R22]--[@R24]^ For example, we determined that endothelial cells are the major fate of *Kit* lineage--traced cells in the heart and that only 1 in 17 000 cardiomyocytes might be produced de novo when an 80% fusion rate is taken into account.^[@R22]^ Sultana and colleagues^[@R23]^ confirmed these results, demonstrating that a large proportion of lineage-traced *Kit* allele--derived cells are endothelial, whereas *Kit* allele lineage--traced cardiomyocytes coexpressing cardiac troponin T in the adult mouse heart were exceptionally rare. Furthermore, a novel Cre/Dre dual recombinase mouse genetic system by He and colleagues,^[@R24]^ which no longer relies on the heterozygosity of the *Kit* allele, showed that c-Kit^+^ cells never produce de novo cardiomyocytes in the adult heart at baseline or with injury. However, the potential to genetically reprogram c-Kit--derived cells and other cardiac mesenchymal cells into cardiomyocytes remains attractive for future development.^[@R25],[@R26]^

The goal of the current study was to determine the contribution of true versus apparent *Kit* allele lineage--derived cardiomyocytes by simultaneously deleting the cardiomyogenic transcription factors *Gata4* and *Gata6*, which, when deleted from mesodermal progenitors during early development, results in acardia and absence of cardiomyocytes.^[@R27]^ We report here that deletion of *Gata4* from c-Kit^+^ cells preferentially impacted a population of c-Kit--expressing endothelial cells and their differentiation state, resulting in defective cardiac capillary formation and immune cell infiltration, which secondarily resulted in a dramatically enhanced rate of fusion of c-Kit--derived immune cells with cardiomyocytes.

Methods
=======

An expanded Methods section is available in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703).

The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure by contacting the corresponding author. The RNA sequencing data were deposited with the GEO database group and given accession number GSE109661.

Animals
-------

All experiments involving mice were approved by the Institutional Animal Care and Use Committee at Cincinnati Children's Hospital Medical Center. *Kit*-Cre recombinase knock-in mice (*Kit*^*Cre*^) and *Kit* mice with a knock-in of the tamoxifen-inducible MerCreMer cDNA (*Kit*^*MCM*^), and *Rosa26* lineage-dependent reporter mice, as well, were each previously described.^[@R22]^ LoxP-targeted *Gata4* (*Gata4*^*fl*^) and *Gata6* (*Gata6*^*fl*^) mice were described previously.^[@R28],[@R29]^ The endothelial specific Tie2^CreERT2^ transgenic mouse model was described elsewhere (Y. Zheng and colleagues, unpublished data).^[@R29a]^ Detailed descriptions of tamoxifen-dosing procedures and euthanasia procedures are provided in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703).

Protein Analysis
----------------

Immunofluorescent stains were performed on cryoembedded tissues,^[@R22]^ and Western blots were performed on cells isolated by fluorescence-activated cell sorting and whole cardiac ventricle tissue as described previously.^[@R30]^ Descriptions of the antibodies used are provided in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703).

Vascular Endothelial Growth Factor-A Overexpression
---------------------------------------------------

An adeno-associated virus-9 vector expressing VEGF-A (vascular endothelial growth factor-A) was prepared and titered ([online-only Data Supplement Methods](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)). Adult *C57Bl/6* mice were administered adeno-associated virus-9--VEGF-A by tail vein injection at concentration of 1×10^12^ viral particles in 200 µL of sterile phosphate-buffered saline.

Bone Marrow Transplantation
---------------------------

Bone marrow transplantations were performed by transplanting bone marrow cells from 6- to 8-week-old donor mice into 8- to 10-week-old recipients. Bone marrow cells (BMCs) were isolated by aseptically flushing femurs and tibiae with Hanks' Balanced Salt Solution. Bone marrow transplant recipient mice first received lethal irradiation (12 Gy in a divided dose 4 hours apart^[@R31]^) and then immediately received a tail vein injection of BMCs at ≈50 million per mouse in 200 µL of Hanks' Balanced Salt Solution.

Retinal Angiogenesis Assay
--------------------------

To observe the superficial vascular plexus to assess endothelial developmental defects, retinal flat mounts were prepared as described earlier.^[@R5]^ In brief, postnatal day (p) 0 mice were given intraperitoneal injections of 200 μg tamoxifen (Sigma T5648; dissolved in 5 μL ethanol and 95 μL peanut oil) for gene inactivation and Tie2 (*Tek* gene) lineage tracing. Neonatal mice were euthanized, their eyes were harvested at p8 and fixed, and the retinas were dissected and mounted for qualitative comparison by enhanced green fluorescent protein (eGFP) fluorescence.

Flow Cytometry and Cell Sorting
-------------------------------

Cells were prepared for flow cytometry studies on cardiac interstitial cells and BMCs as described in detail before.^[@R4],[@R22],[@R32]^ BMCs and cardiac interstitial cells were stained with surface markers using allophycocyanin-conjugated antibodies, and optimum gating strategy was determined using singly labeled controls.

RNA Sequencing Analysis
-----------------------

Endothelial cells were collected as described above for RNA harvest and production of cDNA libraries for sequencing. Libraries were sequenced on the Illumina HiSeq2500 following the manufacturer's protocol. Selected genes were verified by quantitative polymerase chain reaction.

Statistics
----------

See [Methods in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703) for an in-depth description of statistics.

Results
=======

Kit Lineage-Specific Gata4-, Gata6-, and Gata4/6-Deleted Mice
-------------------------------------------------------------

To examine the hypothesis that the deletion of *Gata4* and *Gata6* from c-Kit^+^ CPCs in the heart would block all de novo cardiomyocyte formation, we crossed *Kit*^*MCM*^ mice with mice containing loxP site (fl)--targeted alleles for *Gata4* and *Gata6* (Figure [1](#F1){ref-type="fig"}A). Again, loss of both transcription factors should lead to the inability of CPCs to activate the cardiac transcriptional program required for cardiogenesis.^[@R27],[@R33],[@R34]^ In addition, mice were bred to harbor either the *Rosa26*-loxP-stop-loxP-eGFP (*R26*^*eGFP*^) allele or the *Rosa26*-membrane-Tomato-loxP-Stop-loxP-membrane-eGFP allele^[@R35]^ (*R26*^*mT/mG*^) to trace total *Kit* allele--derived cells in the heart and to examine fusion-derived cardiomyocytes, respectively (Figure [1](#F1){ref-type="fig"}A). Fusion is scored when both the m-eGFP and m-Tomato signals are observed in the same cardiomyocyte, whereas a de novo transdifferentiation event from a c-Kit^+^ CPC would give cardiomyocytes that are only m-eGFP positive. After weaning, mice were put on tamoxifen food for continuous labeling of *Kit* lineage--derived cells (Figure [1](#F1){ref-type="fig"}B). Recombination of these loxP-targeted alleles was assessed by polymerase chain reaction on control and tamoxifen-treated mice, showing specific recombination (Figure [1](#F1){ref-type="fig"}C). Mice were euthanized after 1, 2, and 4 months of tamoxifen treatment for histological and flow cytometry analysis of heart and other tissues. Unexpectedly, total eGFP^+^ cardiomyocytes were increased in mice with deletion of *Gata4/6* or *Gata4*, but not *Gata6* alone with ≈2-fold, 4-fold, and 10-fold increases at 1, 2, and 4 months, respectively (Figure [1](#F1){ref-type="fig"}D through [1](#F1){ref-type="fig"}F). Dual reporter labeling in *Gata4/6*- and *Gata4*-deleted mice revealed significantly more fusion-derived cardiomyocytes (91%--93%) versus 80% to 83% in *Kit*^*MCM*^ *R26*^*mT/mG*^ controls (Figure [1](#F1){ref-type="fig"}G and [1](#F1){ref-type="fig"}H). It is interesting to note that skeletal muscle showed the appearance of eGFP^+^-fused myofibers in *Gata4/6*- and *Gata4*-deleted *Kit*-lineage mice for the first time ([Figure I in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)), whereas other known immune cell--based fusion-prone tissues such as the liver^[@R36],[@R37]^ did not (data not shown). These results collectively show that deletion of *Gata4* from *Kit* allele--derived cells dramatically enhances the relative rate of apparent cardiomyocyte de novo formation, which is potentially attributable to augmented fusion of *Kit* allele--derived immune cells with tissue parenchymal cells as previously shown.^[@R38],[@R39]^

![***Kit* allele-lineage deletion of *Gata4/6* and *Gata4* alone leads to increased lineage-traced cardiomyocytes attributable to fusion.** **A**, Genetic models with the indicated alleles in mice that were crossed. **B**, Experimental design of the protocol used in this figure. **C**, PCR showing recombination (recomb) of the *Gata4* locus with tamoxifen treatment to activate the MerCreMer protein (n=2) or untreated that did not show recombination (n=1) in *Kit*^*MCM*^ *Gata4*/*6*^*fl*/*fl*^ *R26*^*eGFP*^ mice. The analysis used *Kit* lineage tracing in which eGFP^+^ bone marrow cells were first collected. **D**, Immunofluorescent images of cardiac histological sections from *Kit* allele lineage--traced mice with and without *Gata4/6* deletion. Arrows indicate eGFP^+^ cardiomyocytes. **E**, Time-course quantification of the percentage of eGFP^+^ cardiomyocytes within the entire heart in response to *Gata4/6* deletion. Error bars are SEM, n=4 per group (10 sections per heart). \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ at each time point. **F**, Comparative quantitation of the percentage of eGFP^+^ cardiomyocytes within the entire mouse heart in response to *Gata4*, *Gata6*, or double *Gata4/6* deletion in comparison with *Kit* lineage tracing controls. Error bars are SEM, n=4 per group (10 sections per heart). \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ for each genotype. **G**, Immunofluorescent cardiac histological section showing dual reporter evidence of a fusion-derived mTomato^+^ mGFP^+^ cardiomyocyte. **H**, Percentage of fusion-derived *Kit* allele lineage--traced cardiomyocytes (mTomato^+^mGFP^+^) vs. presumed de novo cardiomyocytes (only mGFP^+^). Error bars are SEM, n=4 per group (10 sections per heart). \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*mT/mG*^ for each genotype. eGFP indicates enhanced green fluorescent protein; PCR, polymerase chain reaction; Tam, tamoxifen; and WT, wild type.](cir-138-1012-g001){#F1}

Immunofluorescence staining of Gata4 was frequently positive in total aggregates of BMCs, which is also a known site of c-Kit expression as shown by lineage tracing from the *Kit* allele to produce eGFP expression (Figure [2](#F2){ref-type="fig"}A). It is interesting to note that CD133^+^ endothelial progenitor cells^[@R40]^ from the bone marrow were dramatically enhanced in *Kit* allele-lineage *Gata4/6*--deleted mice in comparison with controls, possibly suggesting a functional role for Gata4 in endothelial cells (Figure [2](#F2){ref-type="fig"}B). Indeed, previous lineage tracing with the *Kit*^*Cre*^ mouse model demonstrated that cardiac *Kit*-derived cell populations in the heart comprised 77% endothelial cells (CD31^+^) and 18% leukocytes (CD45^+^).^[@R22]^ Western blotting of these populations for Gata4 protein demonstrated detectable expression in CD31^+^ endothelial cells but not in CD45^+^ leukocytes or total CD31^−^ CD45^−^ cardiac interstitial cells, or when *Gata4* was deleted from CD31^+^ cells using a Tie2^CreERT2^ transgene (Figure [2](#F2){ref-type="fig"}C). Flow cytometry analysis for CD45^+^ cell content in the hearts of *Kit*-lineage *Gata4/6*- and *Gata4*-deleted mice after 4 months of tamoxifen showed a ≈50% increase in leukocytes (Figure [2](#F2){ref-type="fig"}D and [2](#F2){ref-type="fig"}F) and a ≈60% increase in CD31^+^ endothelial cells in comparison with controls (Figure [2](#F2){ref-type="fig"}E and [2](#F2){ref-type="fig"}G). Taken together, these results show a clear alteration of *Kit* allele--derived populations in the heart in the absence of *Gata4*, such as a dramatic increase in endothelial and CD45 cell content.

![**Cardiac leukocytes and endothelial cells are increased in *Kit* lineage *Gata4*-deleted mice.** **A**, Immunofluorescent staining of Gata4 (red) and DAPI (blue) in bone marrow cells from *Kit*^*MCM*^ *R26*^*eGFP*^ mice (2 months tamoxifen as control) showing some overlap of Kit lineage--traced eGFP^+^ cells with Gata4. **B**, Flow cytometry plots showing CD133^+^ endothelial progenitor cells in *Kit* allele--derived bone marrow cells. **C**, Western blot showing relative Gata4 levels in c-Kit lineages such as CD45^+^ leukocytes, CD31^+^ endothelial cells, and CD31^−^ CD45^−^ interstitial cells, or CD31^+^ cells that were deleted for *Gata4* with the Tie2^CreERT2^ transgene. The positive control was neonatal rat ventricular myocytes (NRVM) loaded at a reduced amount to show the Gata4 band accurately. Although Gapdh was used as a processing and loading control, this protein is more highly expressed in cardiomyocytes and select other cell types. **D**, Immunofluorescent staining of CD45^+^ (white) and DAPI (blue) in cardiac histological sections. **E**, Immunofluorescent staining of CD31^+^ (red) and DAPI (blue) in cardiac histological sections. **F**, Relative quantification of cardiac CD45^+^ cells based on flow cytometry of the interstitial cell fraction from dissociated hearts. Error bars are SEM, n=3 per group. \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ for each genotype. **G**, Relative quantification of cardiac CD31^+^ cells based on flow cytometry from the interstitial cell fraction in dissociated hearts. Error bars are SEM, n=3 per group. \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ for each genotype. DAPI indicates 4′,6-diamidino-2-phenylindole; n.s., nonspecific; SSC-A, side scatter area; and Tam, tamoxifen.](cir-138-1012-g002){#F2}

Bone Marrow Transplant to Identify Cardiovascular Impact of Kit-Lineage Gata4/6 Loss
------------------------------------------------------------------------------------

We hypothesized that the increase in relative *Kit* allele lineage--traced eGFP^+^ cardiomyocytes with *Gata4/6* deletion was attributable to greater leukocyte activity or altered endothelial cell function. To test this hypothesis, we performed a bone marrow transplant that would isolate the impact of *Gata4/6* effects from the hematopoietic compartment. Here, the donating bone marrow was from *Kit*^*MCM*^ *Gata4/6*^*fl/fl*^ *R26*^*eGFP*^ mice (or controls not deleted for *Gata4/6*) that had already undergone full recombination with 6 weeks of prior tamoxifen treatment, which would produce eGFP^+^ circulating immune cells and even endothelial progenitors in recipients (Figure [3](#F3){ref-type="fig"}A). The recipient mice were in the *R26*^*mT*^ genetic background so endogenous cells could be parsed from eGFP^+^ cells. Recipient mice were irradiated, then given the bone marrow transplant and allowed to reconstitute for 8 weeks (Figure [3](#F3){ref-type="fig"}A). Full bone marrow niche reconstitution was confirmed with *Kit*-lineage *R26*^*eGFP*^ recombination (Figure [3](#F3){ref-type="fig"}B) and a general lack of native mTomato^+^ bone marrow (Figure [3](#F3){ref-type="fig"}C). eGFP^+^ cardiomyocytes were observed in the hearts of both control and *Gata4/6*-deleted bone marrow recipients at the same level, which was attributable to fusion because 100% of the cells were both eGFP^+^ and mTomato^+^ (Figure [3](#F3){ref-type="fig"}D and [3](#F3){ref-type="fig"}E). Furthermore, flow cytometry analysis of cardiac interstitial cells revealed no difference in total CD31^+^ cells (Figure [3](#F3){ref-type="fig"}F), demonstrating that *Gata4/6*-deleted bone marrow alone did not recapitulate the phenotype of endothelial expansion or the large relative increase in eGFP^+^ cardiomyocytes observed in the standard *Kit* lineage--traced *Gata4/6*-deleted mice at baseline.

![**Increased cardiomyocyte cell fusion events occur with *Kit* lineage loss of *Gata4/6* within heart cells during bone marrow transplant.** **A**, Experimental design for bone marrow transplant experiments examining the impact of *Gata4/6* loss in *Kit* allele--derived bone marrow on cardiac phenotyping. **B**, Representative FACS plot showing recombination of eGFP^+^ bone marrow from a *Kit* allele lineage--traced donor mouse in a bone marrow transplant recipient. **C**, Representative FACS plot showing effective irradiation and loss of native mTomato^+^ bone marrow in a recipient mouse. **D**, Representative eGFP^+^ mTomato^+^ fusion-derived cardiomyocyte from a cardiac histological section following bone marrow transplant. **E**, Percentage of *Kit* allele--dependent bone marrow--derived eGFP^+^ cardiomyocytes from the entire heart of the indicated mice. Error bars are SEM, n=6 per group (10 sections per heart). **F**, Quantification of cardiac CD31^+^ cells based on flow cytometry from the interstitial fraction in bone marrow transplant recipient hearts from the indicated mice. Error bars are SEM, n=3 per group, *P*=n.s. **G**, Experimental design for bone marrow transplantation to examine the impact of endogenous cardiac loss of *Gata4/6* in *Kit* allele--dependent lineages on the apparent rate of new cardiomyocytes and endothelial cells. **H**, Percentage of wild-type bone marrow--derived mTomato^+^ cardiomyocytes within the entire heart following bone marrow transplant in the indicated mice. Error bars are SEM, n=6 per group (10 sections per heart), \**P*\<0.05 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ recipient. **I**, Quantification from cardiac sections of endogenous endothelial cell number from the *Kit* lineage with 2 months of tamoxifen induction, with and without bone marrow transplantation, in the indicated mice. Error bars are SEM, n=3 per group, *P*=n.s. for all pairwise comparisons. BM indicates bone marrow; BMT, bone marrow transplantation; eGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; n.s., nonspecific; SSC-A, side scatter area; and Tam, tamoxifen.](cir-138-1012-g003){#F3}

Next, we performed a reverse bone marrow transplant strategy. Recipient *Kit*^*MCM*^ mice with or without *Gata4/6* deletion were lethally irradiated at 8 weeks of age, whereafter they received control bone marrow from global *R26*^*mT*^ donors (Figure [3](#F3){ref-type="fig"}G). After 2 months of tamoxifen treatment, mice were euthanized, and cardiac sections were analyzed for mTomato^+^-traced cardiomyocytes within *Gata4/6 Kit* lineage--deleted hearts. The data show an ≈4-fold increase in bone marrow--dependent mTomato^+^ cardiomyocytes with endogenous *Kit* allele-dependent *Gata4/6* deletion in comparison with *Gata4/6* wild-type controls, suggesting that it is the deletion of *Gata4/6* within the existing heart cells that leads to greater apparent cardiomyocyte fusion/labeling (Figure [3](#F3){ref-type="fig"}H). It is important to note that *Kit*-lineage endothelial cell recombination in bone marrow recipient mice was not significantly changed from the ≈8% to 10% of total cardiac endothelium observed in both control and *Gata4/6*-deleted hearts, with and without bone marrow transplant (Figure [3](#F3){ref-type="fig"}I). Together, these experiments demonstrate that a *Kit* lineage--derived cell source endogenous to the heart is the mechanistic basis for the increased ability of wild-type bone marrow progenitor--derived cells (leukocytes) to fuse with cardiomyocytes in vivo.

Endothelial cells are the predominant *Kit* lineage--derived cell type present in the heart,^[@R22]^ suggesting the hypothesis that loss of *Gata4/6* within endogenous cardiac endothelial cells might be mechanistically responsible for greater immune cell infiltration and fusion with cardiomyocytes. To test this hypothesis, we first attempted to alter the differentiation and permeability characteristics of endogenous cardiac endothelial cells by using VEGF-A. Previous work has shown that VEGF-A overexpression leads to weakening of endothelial junctions and increased permeability as these cells partially dedifferentiate or proliferate.^[@R41],[@R42]^ Here, we used a VEGF-A adeno-associated virus-9 to overexpress this factor in the heart of *Kit* lineage--traced mice by tail vein injection ([Figure IIA in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)). VEGF-A overexpression in the heart ([Figure IIB in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)) produced a significant increase in eGFP^+^ cardiomyocytes and leukocyte infiltration ([Figure IIC through IIE in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)), reminiscent of the increases observed in *Gata4/6*-deleted mice.

Global Endothelial Deletion of Gata4
------------------------------------

Despite the modest proportion of *Kit* allele--derived endothelium (≈10%), the loss of *Gata4* in these cells of the heart appeared to cause a global cardiac phenotype of endothelial cell expansion, leukocyte infiltration, and heterotypic cardiomyocyte fusion, suggesting that *Kit* allele--derived endothelial cells were critical in adult vascular maintenance. To further implicate endothelial cells as the causative cell type, we used a tamoxifen-inducible Tie2 Cre-expressing transgenic mouse (Tie2^CreERT2^) to achieve a global and adult endothelial cell--specific deletion of *Gata4*. Tie2 lineage--traced mice were used as controls versus lineage-traced *Gata4*-deleted mice with a continuous tamoxifen regimen, again beginning after weaning (Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B). It is remarkable that after 2 months of tamoxifen, *Gata4*-deleted endothelial cells showed a ≈2-fold increase in Tie2-eGFP^+^ in the heart (Figure [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D) with a significant shift from CD31 high-expressing to CD31 low-expressing cells by flow cytometry (Figure [4](#F4){ref-type="fig"}G and [4](#F4){ref-type="fig"}H), suggesting a less differentiated state. Adult endothelial cell--specific deletion of *Gata4* also resulted in the greater presence of CD45^+^ cells in the heart (Figure [4](#F4){ref-type="fig"}E and [4](#F4){ref-type="fig"}F). In addition, 5-ethynyl-2′-deoxyuridine staining of cardiac sections showed a 3-fold increase in endothelial cell--specific proliferation (Figure [4](#F4){ref-type="fig"}I). Skeletal muscle showed similar results with a shift toward CD31 low-expressing cells and increased 5-ethynyl-2′-deoxyuridine staining ([Figure IIIA and IIIB in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)). Together, these data suggest that loss of *Gata4* in adult endothelial cells alters their differentiated state and produces greater proliferation and leukocyte diapedesis.

![**Global Tie2-lineage deletion of *Gata4* expands the immature endothelial cell population and increases diapedesis.** **A**, Genetic models with the indicated alleles or transgenes in mice that were crossed. **B**, Experimental design of the protocol used in this figure. The Tie2 promoter from the *Tek* gene was used to drive the Cre-ERT2 cDNA. **C**, Representative cardiac histological sections showing Tie2 lineage--traced eGFP^+^ cells (green) from the indicated genotypes of mice. **D**, Quantification of Tie2 lineage--traced eGFP^+^ endothelial cells by flow cytometry from the interstitial fraction in hearts of the indicated lines of mice. Error bars are SEM, n=3 per group, \**P*\<0.05 vs. Tie2^CreERT2^ *R26*^*eGFP*^. **E**, Representative cardiac histological sections showing CD45^+^ cells (white) and DAPI (blue) from the indicated genotypes of mice. **F**, Quantification of CD45^+^ cells by flow cytometry of the interstitial fraction in the hearts of the indicated lines of mice. Error bars are SEM, n=3 per group, \**P*\<0.05 vs. Tie2^CreERT2^ *R26*^*eGFP*^. **G**, Flow cytometry plots showing cardiac CD31^+^ cells with gating to display low- and high-expressing cells from the indicated genotypes of mice. **H**, Quantification of CD31^low^, CD31^high^, and total CD31^+^ cells from flow cytometry of the interstitial fraction of hearts of the indicated genotypes of mice. Error bars are SEM, n=3 per group, *P*=0.0257 for CD31 low comparison, *P*=0.1799 for CD31 high comparison, and *P*\<0.0001 for total CD31+ comparison vs. Tie2^CreERT2^ *R26*^*eGFP*^. **I**, Quantification of EdU^+^ nuclei in Tie2 lineage-traced eGFP^+^ cardiac endothelial cells from cardiac histological sections from the indicated genotypes of mice. Error bars are SEM, n=3 per group (6 EdU-stained sections per heart). \**P*\<0.05 vs. Tie2^CreERT2^ *R26*^*eGFP*^. DAPI indicates 4′,6-diamidino-2-phenylindole; EdU, 5-ethynyl-2′-deoxyuridine; eGFP, enhanced green fluorescent protein; SSC-A, side scatter area; and Tam, tamoxifen.](cir-138-1012-g004){#F4}

To probe even further into the hypothesis that deletion of *Gata4* from *Kit* allele lineage--derived endothelial cells is the primary reason for enhanced bone marrow--derived leukocyte fusion with endogenous cardiomyocytes, we used the *Kit*^*MCM*^ allele together with the Tie2^CreERT2^ transgene in *Gata4*^*fl/fl*^ *R26*^*eGFP*^ mice given continuous tamoxifen (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B). Unfortunately, the Tie2^CreERT2^ transgene is not active in bone marrow; hence, the *Kit*^*MCM*^ allele is needed to label fusigenic immune cells, even though both Cre alleles would inactivate *Gata4* within endothelial cells of the heart (Figure [5](#F5){ref-type="fig"}C). The data again showed significantly greater rates of eGFP^+^-fused cardiomyocytes with *Kit*^*MCM*^ allele--mediated deletion of *Gata4*, and that enhanced deletion of *Gata4* from essentially all endogenous cardiac endothelial cells with the Tie2^CreERT2^ transgene doubled the number of fused cardiomyocytes (Figure [5](#F5){ref-type="fig"}D and [5](#F5){ref-type="fig"}E). To show this even more conclusively, bone marrow transplantation was performed between a *R26*^*mT*^ donor mouse and a Tie2^CreERT2^ *Gata4*^*fl/fl*^ *R26*^*eGFP*^ recipient mouse. In this manner, the recipient mice only have Tie2^CreERT2^ causing *Gata4* deletion in adult endothelial cells without deletion of *Gata4* from bone marrow--derived immune cells or endothelial progenitors. The data again show an enhanced rate of mTomato^+^-fused cardiomyocytes, indicating that the effect is exclusively attributable to defects within endogenous endothelial cells of the heart when *Gata4* is deleted (Figure [5](#F5){ref-type="fig"}G and [5](#F5){ref-type="fig"}H).

![**Global Tie2-lineage deletion of *Gata4* augments appearance of *Kit* lineage-- and bone marrow--labeled cardiomyocytes.** **A**, Genetic models with the indicated alleles or transgenes in mice that were crossed. **B**, Experimental design of the protocol used in this figure. The Tie2 promoter from the *Tek* gene was used to drive the Cre-ERT2 cDNA. **C**, Whole-mount imaging of tibias from mice of the indicated genotypes of mice, highlighting labeled bone marrow cells (green) when the *Kit* lineage--tracing allele was used. **D**, Representative image showing accumulation of *Kit* allele--derived eGFP^+^ cardiomyocytes (arrowheads) in cardiac histological sections from the indicated mouse genotype 2 months after *Gata4* deletion. **E**, Quantification of eGFP^+^ cardiomyocytes from *Kit*^*MCM*^ lineage tracing and *Kit*^*MCM*^ Tie2^CreERT2^ dual lineage tracing, with or without *Gata4* deletion. Error bars are SEM, n=4 per group. \**P*\<0.001 vs. *Kit*^*MCM*^ *R26*^*eGFP*^ controls by 2-way ANOVA. ^\#^*P*\<0.001 vs. dual *Kit*^*MCM*^ Tie2^CreERT2^ *R26*^*eGFP*^ by 2-way ANOVA. **F**, Experimental design for bone marrow transplant of wild-type mTomato^+^ bone marrow into Tie2^CreERT2^ recipient mice with or without *Gata4* deletion. **G**, Representative cardiac histological image of an mTomato^+^ cardiomyocyte (arrowhead) derived from bone marrow following bone marrow transplant from the mice shown in **F**. **H**, Quantification of mTomato^+^ cardiomyocytes from cardiac histological sections of recipient mice of the indicated genotypes following bone marrow transplant. Error bars are SEM, n=6 per group (10 sections per heart). \**P*\<0.05 vs. Tie2^CreERT2^ *R26*^*eGFP*^ recipient mice. eGFP indicates enhanced green fluorescent protein; and Tam, tamoxifen.](cir-138-1012-g005){#F5}

Ex Vivo and Developmental Analysis of Gata4-Deleted Endothelial Cells
---------------------------------------------------------------------

Isolation and culturing of endothelial cells from these genetically modified mouse hearts grossly showed that *Gata4*-replete cells form a typical cobblestone monolayer, whereas *Gata4*-deleted cells are less adherent and show a more torturous morphology (Figure [6](#F6){ref-type="fig"}A). Analysis of cell culture supernatant showed an increase in secretion of angiopoietin-2 and decreased VEGF-A from *Gata4*-deleted endothelial cells, which suggests a vascular-regressive state (Figure [6](#F6){ref-type="fig"}B and [6](#F6){ref-type="fig"}C).^[@R43],[@R44]^ Endothelial cells mixed with Matrigel from these mice were subcutaneously injected into wild-type recipient mice to evaluate vascular tube formation with or without *Gata4* deletion (Figure [6](#F6){ref-type="fig"}D). After 2 weeks, Matrigel plugs were collected and analyzed by confocal microscopy, which showed a limited ability of *Gata4*-deleted endothelial cells to form differentiated vascular networks in comparison with *Gata4*-replete cells using z-stacked confocal microscopy (Figure [6](#F6){ref-type="fig"}E).

![***Gata4*-deleted endothelial cells demonstrate poor differentiation and impaired tube formation.** **A**, eGFP-based imaging of cardiac endothelial cells grown in culture after isolation by fluorescence-activated cell sorting of Tie2-eGFP^+^ CD31^+^ cells from the indicated genotypes of mice. n=3 per group (12 wells of 10 000 cells per heart). Angiopoeitin-2 (**B)** and VEGF-A protein (**C**) quantification from the collected supernatants of cardiac endothelial cell cultures as described in **A**. Error bars are SEM, n=3 per group (3 replicates each). \**P*\<0.05 vs. Tie2^CreERT2^ *R26*^*eGFP*^ at each time point. **D**, Experimental design for ex vivo Matrigel angiogenesis assay from the indicated genotypes of mice over the 2-week time period. **E**, Representative images of tube formation from harvested Matrigel plugs (images presented as flattened z-stack) from the indicated genotypes of mice. The bottom 2 panels are enlarged versions of the smaller windows shown in the top 2 panels. n=4 per group. **F**, Pictures of whole-mount embryos from constitutive *Kit*^*Cre*^ expressing mice demonstrating hemorrhagic phenotype with *Gata4* deletion, but not in control embryos at embryonic day (E) 11.5 of development. n=4. The arrowheads show areas of hemorrhage. **G**, Experimental design for the retinal angiogenesis assay from neonatal times of postnatal day 0 through postnatal day 8. **H**, Representative whole-mount images of postnatal day 8 hearts from control and Tie2^CreERT2^ *Gata4*-deleted hearts. **I**, Representative whole-mount images of neonatal retinas with eGFP imaging based on Tie2^CreERT2^ lineage tracing. The genotypes of mice used are shown, and the bottom 2 panels are higher magnification images of the upper 2 panels. n=6 per group. Angpt-2 indicates angiopoeitin-2; eGFP, enhanced green fluorescent protein; TAM, tamoxifen; and VEGF-A, vascular endothelial growth factor-A.](cir-138-1012-g006){#F6}

Previously, embryonic endothelial-specific deletion of *Gata4* with a constitutive Tie2-Cre transgene demonstrated late embryonic or perinatal lethality because of defective epithelial-to-mesenchymal transition and improper heart valve formation.^[@R45]^ Here, we also observed embryonic lethality with a constitutive *Kit*^*Cre*^ allele to delete *Gata4*. More specifically, constitutive *Kit*^*Cre*^ *Gata4*^*fl/fl*^ mice were found to be hemorrhagic at embryonic day 11.5 with noticeable areas of blood pooling and defective vasculogenesis, leading to embryonic lethality (Figure [6](#F6){ref-type="fig"}F). Constitutive Cdh5^Cre^ (endothelial cell--specific cadherin 5 gene promoter)--mediated deletion of *Gata4* also produced embryonic lethality at the same time (data not shown). Taken together, these results suggest that *Kit* allele--derived cells critically underlie early hemangioblast progenitor cell activity during development and that *Gata4* is essential in these cells for proper vascular development.

Development of the superficial vascular plexus in the neonatal mouse eye begins at birth, with radial outgrowth of endothelial vessels reaching the retinal edge by p8.^[@R46]^ To test the role of Gata4 in retinal vascularization, Tie2-dependent lineage-traced mice were injected with tamoxifen at p0 and harvested at p8 for cardiac phenotyping and retinal angiogenesis (Figure [6](#F6){ref-type="fig"}G). Tie2^CreERT2^ *Gata4*^*fl/fl*^ mice were underdeveloped in comparison with *Gata4*^*fl/fl*^ controls with significantly reduced heart size (Figure [6](#F6){ref-type="fig"}H) and improper patterning of both micro- and macrovasculature in the retina in comparison with Tie2^CreERT2^ *R26*^*eGFP*^ controls (Figure [6](#F6){ref-type="fig"}I). Together, these findings suggest that, in addition to being required embryonically for proper organogenesis, Gata4 is required for continued maturation and maintenance of the adult microvasculature.

Gene Expression Alterations in Adult Gata4-Deficient Endothelial Cells
----------------------------------------------------------------------

To elucidate the molecular basis for Gata4-dependent regulation of endothelial cell differentiation, global RNA sequencing was performed from cardiac endothelial cells isolated from Tie2^CreERT2^ *R26*^*eGFP*^ *Gata4*^*fl/fl*^ mice versus Tie2^CreERT2^ *R26*^*eGFP*^ controls (Figure [7](#F7){ref-type="fig"}). Cells double-positive for endogenous Tie2 lineage tracing (eGFP^+^) and fluorescently labeled for CD31 were obtained by fluorescence-activated cell sorting at 8 weeks of age after 4 weeks of tamoxifen induction. Bioinformatics analysis of the data showed a gene expression signature in which many of the top categories are related to previously known partners and targets of Gata4, and genes related to the function and maintenance of the vasculature (Figure [7](#F7){ref-type="fig"}). Although signature endothelial-defining genes^[@R47]^ (*Cdh5*, *Edn1*, *Kdr*, *Pecam1*, *S1pr1*, *Vwf*) were largely unchanged, well-established regulatory partners of Gata4, including *Fog2 (Zfpm2)*,^[@R48],[@R49]^ *Hand2*,^[@R50]^ *Tbx20*,^[@R51]^ *Dkk3*,^[@R52]^ *Mlc2a (Mly7)*,^[@R53]^ *Sox9*,^[@R54]^ and Klf15,^[@R55]^ were significantly downregulated. A variety of putatively Gata4-regulated genes were also identified using the Harmonizome database,^[@R56]^ many of which have evidence for vascular regulation. For example, *Figf* (*Vegfd*), a predicted target of Gata4, was downregulated in this study and has a known role in endothelial cell regulation.^[@R57]^ A host of genes related in angiogenesis and extracellular matrix formation were impacted with *Gata4* deletion including downregulation of *Itgb4*, *Mmp2*, *Timp2*, *Vcam1*, and *Vcan* and upregulation of *Apold1* and *Has3* (Figure [7](#F7){ref-type="fig"}). In addition, a number of genes related to the cell cycle in endothelial cells were upregulated, such as *E2f7*, *Egr1/2/3*, *Esm1*, and *Plk3*. Verification of mRNA expression differences was performed for most of these gene changes by quantitative reverse transcription polymerase chain reaction, showing consistency with the patterns found by RNA sequencing analysis ([Figure IV in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)). Together, these gene expression data suggest a global impact of *Gata4* deletion on the endothelial cell differentiation gene program, helping to validate the observed differences in proliferation, permeability, and maturation.

![***Gata4*-deleted adult cardiac endothelial cells have dysregulation of cell cycle and angiogenesis-related genes.** RNA sequencing analysis of selected genes from sorted Tie2 lineage--traced eGFP^+^ CD31^+^ cells from hearts of adult mice with or without *Gata4* deletion mediated by the Tie2^CreERT2^ transgene (4 weeks of tamoxifen). Data show fold change in mRNA between *Gata4*-deleted and wild-type endothelial cells, and are organized to highlight genes relevant to previously defined endothelial gene sets or those known to interact with the transcription factor Gata4. n=2 per group (2 combined digested hearts each). See [Methods in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703) for description of bioinformatics and by DESeq2 analysis to show genes differentially expressed. \**P*\<0.05 vs. WT endothelial cells. Eight of the mRNAs shown were not statistically significant by DESeq2 but are included because they were significantly changed by RT-PCR (see [Figure IV in the online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.033703)). ECM indicates extracellular matrix; eGFP, enhanced green fluorescent protein; RT-PCR, reverse transcriptase polymerase chain reaction; and WT, wild type.](cir-138-1012-g007){#F7}

Discussion
==========

Here, we used a genetic approach to determine if the very low level of presumed new cardiomyocyte generation in the heart from the *Kit* lineage really occurs, especially because it was recently reported that adult cardiac *Kit*-dependent CPCs never truly transdifferentiate into cardiomyocytes.^[@R24]^ Indeed, deletion of *Gata4* and *Gata6* simultaneously from *Kit* lineage cells did not reduce the apparent rate of cardiomyocyte labeling in the heart by genetic lineage tracing, and in fact caused as much as a 10-fold increase. Because *Gata4/6* are lacking, it is even more unlikely that new cardiomyocytes could be created from a progenitor cell source, even embryonic stem cells.^[@R27]^ This consideration, along with the very dramatic increase in cell fusion we observed in the current study, suggest that most past results reporting a minor contribution of cardiomyocytes from the *Kit* lineage are likely because of cellular fusion between lineage-traced immune cells and host endogenous cardiomyocytes, or from ectopic induction of the *Kit*^*MCM*^ allele in cardiomyocytes.^[@R24]^ Indeed, our past results, which were subtracted for cellular fusion effects, still showed apparent de novo cardiomyocyte production at ≈1 in 17 000, but, as suggested in the recent literature, this likely reflects ectopic activation of the *Kit*^*Cre*^ allele within rare cardiomyocytes.^[@R24],[@R58]^ Hence, it could be argued that *Kit* lineage--traced cells from any source, whether bone marrow or endogenous to the heart, essentially lack all cardiomyocyte transdifferentiation ability.

In attempting to understand how *Gata4* deletion from the *Kit* lineage produced an apparent 10-fold increase in eGFP^+^ cardiomyocytes, we uncovered an essential role for this transcription factor in regulating the endothelial cell gene program. Although endothelial cell--specific deletion of *Gata4* was shown to cause developmental lethality because of alterations in endothelial cell activity in the cardiac cushions and newly developing heart valves,^[@R45]^ a role for Gata4 in adult cardiac vascular maintenance had not been previously explored. Gata4 was also recently identified as a master regulator of liver sinusoidal endothelial cells, determining their organ specificity and requirement in liver development.^[@R59]^ In addition, in this transition from sinusoidal to capillary formed vascular networks in the liver, the authors observed a distinct shift in CD31^low^ cells to CD31^high^ cells.^[@R59]^ Conversely, we observed a shift toward more permeable vasculature and greater CD31^low^ cells (less differentiated) in the heart and skeletal muscle with deletion of *Gata4*, but this effect was not observed in the liver or lung of our study using Tie2^CreERT2^ (data not shown).

We observed that *Gata6* deletion in both *Kit* allele and endothelial lineages did not overtly alter the angiogenic and vascular processes as shown with *Gata4* deletion. Indeed, we observed that constitutive *Kit*^*Cre*^-expressing *Gata6*^*fl*/*fl*^-deleted mice were not lethal and, when lineage-traced through development to 5 months of age, did not show increases in eGFP^+^ cardiomyocytes. Endothelial cell--specific deletion of *Gata6* with the inducible Tie2-specific Cre mice also did not demonstrate an increase in CD31^+^ cells or increased vascular permeability, suggesting that only Gata4 plays a specific role in regulating the expression of genes involved in endothelial cell biology. We previously observed a similar paradigm at the level of the cardiomyocyte in which angiogenic genes in this cell type were preferentially regulated by Gata4 over Gata6.^[@R29]^

Currently, we speculate that Gata4 is important in endothelial cell maturation/differentiation largely because of the observed ex vivo defective tube formation and the appearance of CD31^low^ endothelial cells in Tie2^CreERT2^ transgene-mediated *Gata4*-deleted mice. The overall increase in CD31^+^ and Tie2 lineage--traced eGFP^+^ cells could be a compensatory response of the cardiac vasculature because of the inability of endothelial cells to maintain secure junctions when Gata4-regulated gene expression is compromised. Thus, new endothelial cells are formed as an attempt to bolster the vasculature, yet leukocytes are still able to infiltrate more easily, giving greater fusion events with endogenous cardiomyocytes. Alternatively, poorly differentiated endothelial cells resulting from the deletion of *Gata4* generate a tissue injury--like signal in these cells that recruits leukocytes and makes them more active. Overall, our results suggest that Gata4 could be used as a therapeutic leverage point in affecting endothelial cell biology for selective therapeutic approaches in humans.
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